• Je něco špatně v tomto záznamu ?

Use of Prostate Specific Antigen Density Combined with Multiparametric Magnetic Resonance Imaging Improves Triage for Prostate Biopsy

M. Záleský, J. Stejskal, V. Adamcova, J. Hrbáček, I. Minarik, A. Pavlicko, J. Votrubova, M. Babjuk, R. Zachoval,

. 2019 ; 103 (1) : 33-40. [pub] 20190508

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006389

Grantová podpora
NV15-27047A MZ0 CEP - Centrální evidence projektů

BACKGROUND: Multi-parametric magnetic resonance imaging (mpMRI)-directed biopsy for prostate cancer (PC) diagnosis improves the detection of clinically significant prostate cancer (CSPC) and decreases the rate of over-diagnosis of insignificant disease. The aim of this study was to investigate the value of mpMRI combined with prostate specific antigen density (PSAD) in the decision making related to the biopsy. METHODS: mpMRI and mpMRI/transrectal ultrasound fusion targeted biopsies with subsequent systematic biopsies were performed in 397 patients (223 biopsy-naïve and 174 with a previous biopsy). Detection rates of (CSPC) and insignificant PC were stratified using the PIRADS score, and the number of avoidable biopsies and missed (CSPC) were plotted against PSAD values of 0.1-0.5 ng/mL2. RESULTS: PIRADS <3 and PSAD <0.2 ng/mL2 were the safest criteria for not performing a biopsy. When applied to the biopsy-naïve group, 21.5% (48/223) of the biopsies could have been avoided and 3.7% (3/82) of CSPC would have been missed. In the repeat biopsy group, 12.6% (22/174) of biopsies could have been avoided and 6.9% (4/58) of (CSPC) would have been missed. CONCLUSIONS: A combination of mpMRI and PSAD might reduce the number of biopsies performed with the cost of missing <4% of CSPC.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006389
003      
CZ-PrNML
005      
20200522093551.0
007      
ta
008      
200511s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1159/000500350 $2 doi
035    __
$a (PubMed)31067560
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Záleský, Miroslav $u Department of Urology, Thomayer Hospital, Prague, Czechia. 1st Faculty of Medicine, Department of Urology, Charles University, Prague, Czechia.
245    10
$a Use of Prostate Specific Antigen Density Combined with Multiparametric Magnetic Resonance Imaging Improves Triage for Prostate Biopsy / $c M. Záleský, J. Stejskal, V. Adamcova, J. Hrbáček, I. Minarik, A. Pavlicko, J. Votrubova, M. Babjuk, R. Zachoval,
520    9_
$a BACKGROUND: Multi-parametric magnetic resonance imaging (mpMRI)-directed biopsy for prostate cancer (PC) diagnosis improves the detection of clinically significant prostate cancer (CSPC) and decreases the rate of over-diagnosis of insignificant disease. The aim of this study was to investigate the value of mpMRI combined with prostate specific antigen density (PSAD) in the decision making related to the biopsy. METHODS: mpMRI and mpMRI/transrectal ultrasound fusion targeted biopsies with subsequent systematic biopsies were performed in 397 patients (223 biopsy-naïve and 174 with a previous biopsy). Detection rates of (CSPC) and insignificant PC were stratified using the PIRADS score, and the number of avoidable biopsies and missed (CSPC) were plotted against PSAD values of 0.1-0.5 ng/mL2. RESULTS: PIRADS <3 and PSAD <0.2 ng/mL2 were the safest criteria for not performing a biopsy. When applied to the biopsy-naïve group, 21.5% (48/223) of the biopsies could have been avoided and 3.7% (3/82) of CSPC would have been missed. In the repeat biopsy group, 12.6% (22/174) of biopsies could have been avoided and 6.9% (4/58) of (CSPC) would have been missed. CONCLUSIONS: A combination of mpMRI and PSAD might reduce the number of biopsies performed with the cost of missing <4% of CSPC.
650    _2
$a senioři $7 D000368
650    12
$a biopsie $7 D001706
650    _2
$a rozhodování $7 D003657
650    _2
$a časná detekce nádoru $x normy $7 D055088
650    _2
$a lidé $7 D006801
650    _2
$a ultrazvukem navigovaná biopsie $7 D061705
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lékařská onkologie $x normy $7 D008495
650    _2
$a lidé středního věku $7 D008875
650    12
$a multiparametrická magnetická rezonance $7 D000081364
650    _2
$a prostata $x patologie $7 D011467
650    _2
$a prostatický specifický antigen $x krev $7 D017430
650    _2
$a nádory prostaty $x diagnostické zobrazování $x patologie $7 D011471
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a ultrasonografie $7 D014463
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stejskal, Jiri $u Department of Urology, Thomayer Hospital, Prague, Czechia.
700    1_
$a Adamcova, Vanda $u Department of Urology, Thomayer Hospital, Prague, Czechia.
700    1_
$a Hrbáček, Jan $u Department of Urology, Thomayer Hospital, Prague, Czechia.
700    1_
$a Minarik, Ivo $u 2nd Faculty of Medicine, Department of Urology, Charles University, Prague, Czechia.
700    1_
$a Pavlicko, Adam $u Department of Radiology, Thomayer Hospital, Prague, Czechia.
700    1_
$a Votrubova, Jana $u Department of Radiology, Thomayer Hospital, Prague, Czechia.
700    1_
$a Babjuk, Marek $u 2nd Faculty of Medicine, Department of Urology, Charles University, Prague, Czechia.
700    1_
$a Zachoval, Roman $u Department of Urology, Thomayer Hospital, Prague, Czechia, roman.zachoval@ftn.cz. 1st Faculty of Medicine, Department of Urology, Charles University, Prague, Czechia, roman.zachoval@ftn.cz. 3rd Faculty of Medicine, Department of Urology, Charles University, Prague, Czechia, roman.zachoval@ftn.cz.
773    0_
$w MED00004616 $t Urologia internationalis $x 1423-0399 $g Roč. 103, č. 1 (2019), s. 33-40
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31067560 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200522093549 $b ABA008
999    __
$a ok $b bmc $g 1525247 $s 1096445
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 103 $c 1 $d 33-40 $e 20190508 $i 1423-0399 $m Urologia internationalis $n Urol Int $x MED00004616
GRA    __
$a NV15-27047A $p MZ0
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace